Amplatzer Amulet China Post Market Study (PMS)

Last updated: February 6, 2025
Sponsor: Abbott Medical Devices
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Chest Pain

Arrhythmia

Cardiac Disease

Treatment

Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder

Clinical Study ID

NCT06189365
ABT-CIP-10491
CRD_1028
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to prospectively evaluate the safety and effectiveness of the Amplatzer Amulet LAA occluder in a Chinese patient population indicated for use of this device.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Documented non-valvular atrial fibrillation and contraindicated for long-term oralanticoagulation, or in those who are taking oral warfarin but still develop strokeor relevant events

  2. Meets the current device indications and per physician discretion for Amulet implant

  3. Able to provide written Informed Consent prior to any study related procedures

  4. 18 years of age or older at the time of enrolment

Exclusion

Exclusion Criteria:

  1. With the presence of intracardiac thrombus

  2. With active endocarditis or other infections producing bacteremia

  3. Patients whose low risk of stroke (CHA2DS2-VASC score is 0 or 1) or bleeding (HAS-BLED score < 3)

  4. Where placement of the device would interfere with any intracardiac or intravascularstructures

  5. Has a life expectancy of less than 2 years due to any condition

  6. Currently participating or planning on participating during the follow up period ofthis study in a clinical study that includes an active treatment arm or a concurrentclinical study which may confound the results of this trial

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder
Phase:
Study Start date:
January 30, 2024
Estimated Completion Date:
January 31, 2030

Study Description

Atrial fibrillation (AF) is the most common sustained heart rhythm disorder. During AF, chaotic electrical activity results in rapid, uncoordinated, and insufficient contractions of the atrial chambers. Stagnation of blood flow in the left atrium (LA) can lead to hypercoagulability. The left atrial appendage (LAA), given its location and complex shape is often the primary site of stasis and thus increases the risk for thrombus formation. Approximately 90% of all thrombi in patients with non-valvular AF (NVAF) forming in the LA originate in the LAA.

Patients with NVAF are at an increased risk of systemic embolism and stoke due to the potential for clot forming in the LAA. OAC is the recommended first-line therapy for NVAF at increased risk of stroke, however, many patients have relative or absolute contraindications to taking OACs. LAAO offers a non-pharmacological option for stroke risk reduction in these patients unable to take OAC.

The Amulet occluder is Abbott's second-generation LAA occlusion device. It received CE Mark in 2013, and FDA approval in August 2021. Observational studies performed in multiple geographies show that the Amulet occluder can be safely implanted with good procedural outcomes and reduce the risk of stroke as compared to a predicted rate without the need for anticoagulation in most patients. This led to the National Medical Products Administration (NMPA) approval of the Amulet occluder in 2020.

The purpose of this study is to prospectively evaluate the safety and effectiveness of the Amplatzer Amulet LAA occluder in a Chinese patient population indicated for use of this device.

Connect with a study center

  • University of Hong Kong-Shenzhen Hospital

    Shenzhen, Guangdong 518009
    China

    Site Not Available

  • Wuhan Asia Heart Hospital

    Wuhan, Hubei 430022
    China

    Site Not Available

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan 410013
    China

    Site Not Available

  • Xiangya Hospital Zhuzhou Central South University

    Zhuzhou, Hunan 412007
    China

    Site Not Available

  • Xianyang Hospital Of Yan'an University

    Xianyang, Shaanxi
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.